Barclays Starts Moonlake Immunotherapeutics (MLTX) at Equalweight, 'Risk/reward balanced'
Tweet Send to a Friend
(Updated - June 15, 2023 5:58 AM EDT)
Barclays analyst Leon Wang initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst Leon Wang initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
